Tumor-specific vaccine therapy using the epitope peptide derived from a tumor antigen gene for the upper urinary tract cancer

• Project/Area Number: 20591864
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Urology
• Research Institution: Iwate Medical University
• Principal Investigator: FUJIOKA Tomoaki Iwate Medical University, 医学部, 教授 (80173409)
• Co-Investigator(Kenkyū-buntansha): 小原 航 岩手医科大学, 医学部, 講師 (90337155) ; 兼平 貢 岩手医科大学, 医学部, 助教 (50453303)
• Project Period (FY): 2008 – 2010
• Project Status: Completed (Fiscal Year 2010)
• Budget Amount: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000); Fiscal Year 2010: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2009: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2008: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
• Keywords: 上部尿路上皮癌 / 腫瘍特異的 / ペプチドワクチン / 個別化医療 / ペプチドワクチシ

Research Abstract

We were stage and grade-independent, and novel tumor antigen MPHOSPH1 and DEPDC1 protein high frequently expressed in the upper urinary tract cancer with stage and grade-independent. The peptide vaccine treatmnet for the upper urinary tract cancer is safe and is useful as postoperative prevention of recurrence. TIL is involved in the antitumor effect.

Research Products

• [Journal Article] Serum Selenium Levels in Hemodialysis Patients Are Significantly Lower than Those in Healthy Controls. (2011)
  • Author(s): Fujishima Y, Ohsawa M, Itai K, Kato K, Tanno K, Turin TC, Onoda T, Endo S, Okayama A, Fujioka T.
  • Journal Title: Blood Purif Volume: 32 Pages: 43-47
  • Peer Reviewed
• [Journal Article] Cell-permeable peptide DEPDC1-ZNF224 interferes with transcriptional repression and oncogenicity in bladder cancer cells. (2010)
  • Author(s): Harada Y, Kanehira M, Fujisawa Y, Takata R, Shuin T, Miki T, Fujioka T, Nakamura Y, Katagiri T
  • Journal Title: Cancer Res 70 Pages: 5829-39
• [Journal Article] Successful outcomes using combination therapy of interleukin-2 and interferon-alpha for renal cell carcinoma patients with lung metastasis. (2010)
  • Author(s): Akaza H, Kawai K, Tsukamoto T, Fujioka T, Tomita Y, Kitamura T, Ozono S, Miki T, Naito S, Zembutsu H, Nakamura Y.
  • Journal Title: Jpn J Clin Oncol Volume: 40 Pages: 684-689
  • Peer Reviewed
• [Journal Article] Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma. (2010)
  • Author(s): Tan MH, Wong CF, Tan HL, Yang XJ, Ditlev J, Matsuda D, Khoo SK, Sugimura J, Fujioka T, Furge KA, Kort E, Giraud S, Ferlicot S, Vielh P, Amsellem-Ouazana D, Debre B, Flam T, Thiounn N, Zerbib M, Benoit G, Droupy S, Molinie V, Vieillefond A, Tan PH, Richard S, Teh BT.
  • Journal Title: BMC Cancer Volume: 10 Pages: 196-196
  • Peer Reviewed
• [Journal Article] 5alphaDH-DOC(5alpha-dihydro-deoxycorticosterone)activates androgenreceptor in castration-resistant prostate cancer. (2010)
  • Author(s): Uemura M, Honma S, Chung S, Takata R, Furihata M, Nishimura K, Nonomura N, Nasu Y, Miki T, Shuin T, Fujioka T, Okuyama A, Nakamura Y, Nakagawa H.
  • Journal Title: Cancer Sci. Volume: 101 Pages: 1897-1904
  • Peer Reviewed
• [Journal Article] Cell-permeable peptide DEPDC1-ZNF224 interferes with transcriptional repression and oncogenicity in bladder cancer cells. (2010)
  • Author(s): Harada Y, Kanehira M, Fujisawa Y, Takata R, Shuin T, Miki T, Fujioka T, Nakamura Y, Katagin T.
  • Journal Title: Cancer Res Volume: 70 Pages: 5829-5839
  • Peer Reviewed
• [Journal Article] Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. (2010)
  • Author(s): Takata R, Akamatsu S, Kubo M, Takahashi A, Hosono N, Kawaguchi T, Tsunoda T, Inazawa J, Kamatani N, Ogawa O, Fujioka T, Nakamura Y, Nakagawa H.
  • Journal Title: Nat Genet. Volume: 42 Pages: 751-754
  • Peer Reviewed
• [Journal Article] A functional variant in NKX3.1 associated with prostate cancer susceptibility down-regulates NKX3.1 expression. (2010)
  • Author(s): Akamatsu S, Takata R, Ashikawa K, Hosono N, Kamatani N, Fujioka T, Ogawa O, Kubo M, Nakamura Y, Nakagawa H.
  • Journal Title: Hum Mol Genet Volume: 19 Pages: 4265-4272
  • Peer Reviewed
• [Journal Article] Nuclear import mechanism for myocardin family members and their correlation with vascular smooth muscle cell phenotype. (2010)
  • Author(s): Nakamura S, Hayashi K, Iwasaki K, Fujioka T, Egusa H, Yatani H, Sobue K.
  • Journal Title: J Biol Chem Volume: 285 Pages: 37314-37323
  • Peer Reviewed
• [Journal Article] Testis-specific protein on Y chromosome (TSPY) represses the activity of the androgen receptor in androgen-dependent testicular germ-cell tumors. (2010)
  • Author(s): Akimoto C, Ueda T, Inoue K, Yamaoka I, Sakan M, Obara W, Fujioka T, Nagahara A, Nonomura N, Tsutsumi S, Aburatani H, Miki T, Matsumoto T, Kitagawa H, Kato S
  • Journal Title: Proc Natl Acad Sci USA Volume: 107 Pages: 19891-6
  • Peer Reviewed
• [Journal Article] Evidence-based clinical practice guidelines for renal cell carcinoma (Summary-JUA 2007 Edition). (2009)
  • Author(s): Fujioka T, Obara W
  • Journal Title: Int J Urol 16 Pages: 339-353
  • NAID: 10025197247
  • Peer Reviewed
• [Journal Article] Novel lipogenic enzyme ELOVL7 is involved in prostate cancer growth through saturated long-chain fatty acid metabolism. (2009)
  • Author(s): Tamura K, Makino A, Hullin-Matsuda F, Kobayashi T, Furihata M, Chung S, Ashida S, Miki T, Fujioka T, Shuin T, Nakamura Y, Nakagawa H.
  • Journal Title: Cancer Res. 69 Pages: 8133-8140
  • Peer Reviewed
• [Journal Article] Overexpression of the potential kinase serine/ threonine/tyrosine kinase 1 (STYK 1) in castration-resistant prostate cancer. (2009)
  • Author(s): Chung S, Tamura K, Furihata M, Uemura M, Daigo Y, Nasu Y, Miki T, Shuin T, Fujioka T, Nakamura Y, Nakagawa H.
  • Journal Title: Cancer Sci. 100 Pages: 2109-2114
  • NAID: 10027196974
  • Peer Reviewed
• [Journal Article] Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aqqressive prostate cancer (2009)
  • Author(s): Tamura K, Fujioka T, et al
  • Journal Title: Cancer Sci 25(Epub ahead of print)
  • Peer Reviewed
• [Journal Article] Involvement of TMEM22 overexpression in growth of renal cell carcinoma cells. (2009)
  • Author(s): Dobashi S, Fujioka T, et a1
  • Journal Title: Onool Rep 21・2 Pages: 305-312
  • Peer Reviewed
• [Journal Article] Prospective study of combined treatment with interferon-alpha and active vitamin D3 for Japanese patients with metastatic renal cell carcinom (2008)
  • Author(s): Obara W, Fujioka T, et al
  • Journal Title: Int J Urol 15・9 Pages: 794-799
  • Peer Reviewed
• [Journal Article] Over expression of hypoxia-inducible protein 2, hypoxia-induoible factor-lalpha and nuclear factor kappaB is putatvely involved acquired renal cyst formation and subsequent tumor transfomation in patients with e (2008)
  • Author(s): Konda R, Fujioka T, et al
  • Journal Title: J Urol 180・2 Pages: 481-485
  • Peer Reviewed
• [Journal Article] Rho/Rho-associated kinase signal regulates myogenic differentiation via myocardin-related transcription factor-A/Smad-dependent transcription of the 1d3 gene (2008)
  • Author(s): Iwasaki K, Fujioka T, et al
  • Journal Title: J Biol Chera 283・30 Pages: 21230-41
  • Peer Reviewed
• [Presentation] Clinical practice for JUA RCC guideline (2009)
  • Author(s): Tomoaki Fujioka
  • Organizer: 第47回日本癌治療学会
  • Place of Presentation: 横浜
• [Book] 膀胱腫瘍 (2010)
  • Author(s): 藤岡知昭
  • Total Pages: 2
  • Publisher: 医学書院
• [Book] 前立腺癌診療 こんなときどうするQ&A -前立腺癌スクリーニングではPSA検査が最も精度が高いそうですが、直腸診は必要ないのでしょうか?- (2010)
  • Author(s): 藤岡知昭
  • Total Pages: 2
  • Publisher: 中外医学社
• [Book] EBM透析医療 II.血液浄化法の選択と条件設定 3.急性腎障害に対し、どのタイミングで血液浄化療法を開始し、どの治療法を選択するべきか? (2010)
  • Author(s): 阿部貴弥, 藤岡知昭 (編集:深川雅史, 秋澤忠男)
  • Total Pages: 5
  • Publisher: 中外医学社
• [Book] インフォームドコンセントのための図解シリーズ 17.膀胱癌 (2010)
  • Author(s): 小原航, 藤岡知昭(監修:吉田修, 編集:大園誠一郎, 赤座英之)
  • Total Pages: 8
  • Publisher: 医薬ジャーナル
• [Book] Urologic Surgery-6 尿路変更術・尿路再建術 Psoas hitch法 (2010)
  • Author(s): 小原航, 丹治進, 藤岡知昭
  • Total Pages: 8
  • Publisher: MEDICAL VIEW
• [Book] 腎・泌尿器癌-基礎・臨床研究のアップデート I.腎癌 臨床研究 診断 腎癌診療ガイドライン) (2010)
  • Author(s): 小原航, 藤岡知昭
  • Total Pages: 6
  • Publisher: 日本臨床
• [Book] 腎・泌尿器癌-基礎・臨床研究のアップデート I.腎癌 臨床研究 治療 腎癌の分子標的治療 その他の分子標的薬 (2010)
  • Author(s): 小原航, 藤岡知昭
  • Total Pages: 4
  • Publisher: 日本臨床
• [Book] がんペプチドワクチン療法(中村祐輔編)腎がん新規腫瘍抗原(HIG2)を利用したワクチン療法 (2009)
  • Author(s): 小原航、高田亮、藤岡知昭
  • Publisher: 中山書店
• [Book] がんペプチドワクチン療法(中村祐輔編)膀胱がん新規腫瘍抗原(MPHOSPH1, DEPDC1)を利用したワクチン療法 (2009)
  • Author(s): 小原航、高田亮、兼平貢、藤岡知昭
  • Publisher: 中山書店
• [Book] がんペプチドワクチン療法 腎がん 新規腫瘍抗原(HIG2)を利用したワクチン療法 (2009)
  • Author(s): 小原航、高田亮、兼平貢、藤岡知昭(中村祐輔 編)
  • Total Pages: 5
  • Publisher: 中山書店
• [Book] 【尿路上皮癌の診断と治療Update】膀胱癌組織の遺伝子発現解析によるMVACネオアジュバント化学療法の効果予測 (2008)
  • Author(s): 高田亮, 片桐豊雅, 兼平貢, 小原航, 中村祐輔, 藤岡知昭
  • Publisher: Urology View
• [Book] Renal Cell Carcinoma (2008)
  • Author(s): Obara W, Fujioka T
  • Total Pages: 6
  • Publisher: Gan To Kagaku Ryouho
• [Remarks] ホームページ等